EMEA-002969-PIP01-21

Table of contents

Key facts

Active substance
  • Zibotentan
  • dapagliflozin propanediol monohydrate
Therapeutic area
Other
Decision number
P/0249/2021
PIP number
EMEA-002969-PIP01-21
Pharmaceutical form(s)
  • Capsule, hard
  • tablets
Condition(s) / indication(s)
Treatment of chronic kidney disease
Route(s) of administration
Oral use
Contact for public enquiries
AstraZeneca AB

Tel.  +46 8 553 24400
E-mail: paediatrics@astrazeneca.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating